In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells

Cancer Research
Pierfrancesco TassoneNikhil Munshi

Abstract

HuN901 is a humanized monoclonal antibody that binds with high affinity to CD56, the neuronal cell adhesion molecule. HuN901 conjugated with the maytansinoid N(2')-deacetyl-N(2')-(3-mercapto-1-oxopropyl)-maytansine (DM1), a potent antimicrotubular cytotoxic agent, may provide targeted delivery of the drug to CD56 expressing tumors. Based on gene expression profiles of primary multiple myeloma (MM) cells showing expression of CD56 in 10 out of 15 patients (66.6%) and flow cytometric profiles of MM (CD38(bright)CD45(lo)) cells showing CD56 expression in 22 out of 28 patients (79%), we assessed the efficacy of huN901-DM1 for the treatment of MM. We first examined the in vitro cytotoxicity and specificity of huN901-DM1 on a panel of CD56(+) and CD56(-) MM cell lines, as well as a CD56(-) Waldenstrom's macroglobulinemia cell line. HuN901-DM1 treatment selectively decreased survival of CD56(+) MM cell lines and depleted CD56(+) MM cells from mixed cultures with a CD56(-) cell line or adherent bone marrow stromal cells. In vivo antitumor activity of huN901-DM1 was then studied in a tumor xenograft model using a CD56(+) OPM2 human MM cell line in SCID mice. We observed inhibition of serum paraprotein secretion, inhibition of tumor grow...Continue Reading

References

Dec 1, 1978·Cancer Treatment Reviews·B F Issell, S T Crooke
Sep 19, 1975·Science·S RemillardS M Kupchan
Jul 1, 1986·The Journal of Experimental Medicine·R E SchmidtJ Ritz
Oct 1, 1985·Proceedings of the National Academy of Sciences of the United States of America·K L CrossinG M Edelman
Feb 1, 1994·Proceedings of the National Academy of Sciences of the United States of America·M A RoguskaB C Guild
Aug 6, 1996·Proceedings of the National Academy of Sciences of the United States of America·C LiuR V Chari
Feb 1, 1996·Leukemia & Lymphoma·U KaiserM Oldenburg
Feb 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·T J LynchJ Ritz
Apr 1, 1997·British Journal of Haematology·A C RawstronG J Morgan
Nov 10, 1998·Critical Reviews in Eukaryotic Gene Expression·R A FarahE S Vitetta
Nov 18, 1998·Current Opinion in Oncology·G A Leget, M S Czuczman
Apr 13, 2000·Cancer Control : Journal of the Moffitt Cancer Center·J A Lust, K A Donovan
Oct 2, 2001·Critical Reviews in Oncology/hematology·L S Schwartzberg
Mar 22, 2002·Nature Reviews. Cancer·P Carter
Jun 13, 2002·British Journal of Haematology·Naohi SaharaRyuzo Ohno
Dec 3, 2002·Nature Reviews. Cancer·Teru Hideshima, Kenneth C Anderson
Jan 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anthony W TolcherEric K Rowinsky
Jul 9, 2003·Immunological Reviews·Teru HideshimaKenneth C Anderson

❮ Previous
Next ❯

Citations

Dec 7, 2005·Cancer Chemotherapy and Pharmacology·Joseph A ReddyChristopher P Leamon
Mar 6, 2009·Cancer Chemotherapy and Pharmacology·Donato CoscoMassimo Fresta
Jan 30, 2010·International Journal of Hematology·Ritsuro SuzukiTomoki Naoe
Aug 21, 2007·Accounts of Chemical Research·Ravi V J Chari
Aug 20, 2011·Leukemia·N W C J van de DonkH M Lokhorst
Mar 30, 2007·Nature Clinical Practice. Oncology·Alejandro D Ricart, Anthony W Tolcher
Jun 10, 2008·The Cancer Journal·Paul J Carter, Peter D Senter
May 12, 2005·Blood·Pierfrancesco TassoneNikhil C Munshi
May 25, 2011·Haematologica·Djordje AtanackovicNicolaus Kröger
Mar 1, 2011·Therapeutic Delivery·Victor S Goldmacher, Yelena V Kovtun
Dec 3, 2005·Proceedings of the National Academy of Sciences of the United States of America·Cary D AustinSuzie J Scales
Jul 22, 2008·Nature Biotechnology·Jagath R JunutulaWilliam Mallet
Jun 1, 2012·Clinical & Developmental Immunology·Ivetta DanyleskoArnon Nagler
Nov 3, 2011·Bone Marrow Research·Yu-Tzu Tai, Kenneth C Anderson
Oct 8, 2015·Leukemia & Lymphoma·Valeria MagarottoAntonio Palumbo
May 24, 2011·Expert Opinion on Investigational Drugs·Puja SapraHans-Peter Gerber
Dec 22, 2007·Expert Opinion on Drug Delivery·Michael J BrumlikTyler J Curiel
Nov 17, 2006·Expert Opinion on Investigational Drugs·Sara BringhenAntonio Palumbo
May 23, 2013·Expert Opinion on Biological Therapy·Nicola AmodioPierfrancesco Tassone
Dec 15, 2010·Expert Opinion on Investigational Drugs·Andrew G PolsonVanitha Ramakrishnan
Mar 1, 2006·Expert Opinion on Biological Therapy·Hongsheng Xie, Walter A Blättler
Jan 23, 2016·British Journal of Haematology·Djordje AtanackovicTim Luetkens
Mar 2, 2016·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Pawel Robak, Tadeusz Robak
Dec 27, 2015·Hematology/oncology and Stem Cell Therapy·Syed Z A ZaidiAli Al-Shanqeeti
May 6, 2009·Current Opinion in Chemical Biology·Peter D Senter
Nov 13, 2007·Hematology/oncology Clinics of North America·Constantine S MitsiadesDaniel R Carrasco
Oct 24, 2007·Cancer Letters·Markus Jensen, Frank Berthold
Nov 6, 2015·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Joshua Seth EatonChristopher J Murphy
Jul 15, 2015·Critical Reviews in Oncology/hematology·Ayed O AyedJan S Moreb
Aug 6, 2005·Protein Science : a Publication of the Protein Society·Lintao WangWei Zhang
Mar 6, 2008·British Journal of Haematology·Prashant KapoorPhilip R Greipp
Nov 24, 2012·British Journal of Clinical Pharmacology·John M Lambert
Mar 20, 2013·European Journal of Haematology·Alessandro AllegraCaterina Musolino
Jul 20, 2012·Cancer Science·Hiroshi YasuiKohzoh Imai
Jul 14, 2010·British Journal of Haematology·Asher A Chanan-KhanDonna E Reece
Jan 30, 2014·International Journal of Cancer. Journal International Du Cancer·Mingjun ZhangQing Yi
Jun 27, 2006·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Malay ChatterjeePierfrancesco Tassone
Jul 20, 2005·Best Practice & Research. Clinical Haematology·Teru HideshimaKenneth C Anderson
Sep 13, 2015·Blood Reviews·Tomas Jelinek, Roman Hajek
Mar 1, 2015·The AAPS Journal·Gadi G Bornstein

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Adhesion Molecules in the Brain

Cell adhesion molecules found on cell surface help cells bind with other cells or the extracellular matrix to maintain structure and function. Here is the latest research on their role in the brain.

Adhesion Molecules in Health and Disease

Cell adhesion molecules are a subset of cell adhesion proteins located on the cell surface involved in binding with other cells or with the extracellular matrix in the process called cell adhesion. In essence, cell adhesion molecules help cells stick to each other and to their surroundings. Cell adhesion is a crucial component in maintaining tissue structure and function. Discover the latest research on adhesion molecule and their role in health and disease here.